Active Ingredient History
Levosimendan (INN) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax. Overall the drug has a two fold mechanism of action. It leads to greater inotrophy by increasing the calcium sensitivity as it binds to troponin and this results in a greater positive inotrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased preload and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved for use in the United States yet. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 3)
Aortic Coarctation (Phase 4)
Aortic Valve Stenosis (Phase 4)
Cardiac Output, Low (Phase 4)
Cardiomyopathies (Phase 4)
Cardiopulmonary Bypass (Phase 4)
Cardio-Renal Syndrome (Phase 3)
Cardiovascular Diseases (Phase 4)
Coronary Artery Bypass (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 2)
Dyslipidemias (Phase 3)
Echocardiography, Transesophageal (Phase 2/Phase 3)
Extracorporeal Membrane Oxygenation (Phase 3)
General Surgery (Phase 3)
Heart Arrest (Phase 4)
Heart Defects, Congenital (Phase 2)
Heart Disease Risk Factors (Phase 3)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Heart Valve Diseases (Phase 4)
Hemodynamics (Phase 4)
Hip Fractures (Phase 4)
Hypertension, Pulmonary (Phase 3)
Hypertrophy, Left Ventricular (Phase 4)
Ischemic Attack, Transient (Phase 2)
Mitral Valve Stenosis (Phase 4)
Muscle Contraction (Phase 4)
Muscle Weakness (Phase 2/Phase 3)
Myocardial Infarction (Phase 4)
Myocardial Stunning (Phase 4)
Myocardium (Phase 4)
Pharmacokinetics (Phase 4)
Renal Insufficiency (Phase 4)
Respiratory Distress Syndrome (Phase 3)
Shock, Cardiogenic (Phase 4)
Shock, Septic (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stroke (Phase 2)
Subarachnoid Hemorrhage (Phase 2)
Thoracic Surgery (Phase 4)
Transcatheter Aortic Valve Replacement (Phase 4)
Tricuspid Valve (Phase 3)
Ventricular Dysfunction, Right (Phase 2/Phase 3)
Weaning (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue